CHEK2 and breast cancer: In oncology, particularly in breast cancer (mammary carcinoma), long-read sequencing can enhance the detection of variants in genes such as BRCA1, BRCA2, TP53, PIK3CA, and CHEK2, which are critical for risk stratification, therapeutic targeting, and treatment response monitoring.